Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Improved diagnostics priority in Global Plan to End TB

The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in 8 years. A key recommendation of the report is to universally replace sputum microscopy with rapid molecular diagnostics.
  • November 21, 2022
  • Human health, Phage-based diagnostics
Global Plan to End TB cost of inaction

Costed public health plan with high ROI aims to cut deaths by 90% in 8 years

The Global Plan to End TB 2023-2030, launched on the 6th July 2022, is a detailed and costed action plan for ending TB as a public health challenge. It aims to cut 26.5 million cases in eight years. A key recommendation of the report is to universally replace sputum microscopy with rapid molecular diagnostics as the initial diagnostic test.

In 2020 it was estimated that nearly 10 million people had tuberculosis (TB), with deaths increased for the first time in over a decade. 4,100 people die each day from this treatable disease.

More than a third of people with TB in 2020 went undiagnosed, with each untreated case infecting 15 more

The Global Plan to End TB 2023–2030 is an inclusive document developed in collaboration with numerous partners, stakeholders and experts. It provides a clear roadmap and the most detailed budget estimates to date for ending TB as a public health challenge by 2030, in line with the UN Sustainable Development Goals.

The investment case for the estimated budget of US$249.98 billion required shows impressive returns on investment – US$40 for every dollar invested – and points out the huge human cost of inaction.

This Global Plan also re-imagines TB care to be focused on people and responsive to gender needs, taking into account the mental health challenges and the interplay with different diseases like HIV/AIDS. The plan offers robust guidance on the R&D investments needed to accelerate the development of new TB vaccines, diagnostics and medicines.

The report identifies that rapid and accessible TB diagnosis is the first step in providing effective treatment and saving lives, stating: “Many countries today still rely on sputum microscopy as the initial diagnostic test for TB. Rapid molecular tests need to replace sputum microscopy as the initial diagnostic test.”

It also recognises the need to address the massive reservoir of TB infection, where there are no clinical symptoms, as these may eventually progress to active disease. It recognises that the current tuberculin skin test (TST) is insufficient as it can show a false-positive result in people who have received the Bacille Calmette-Guérin (BCG) vaccine.

The Global Plan to End TB makes the following recommendations for diagnostics:

  • Develop rapid, affordable tests for diagnosis or triage that do not rely exclusively on sputum and are used at the point of care.
  • Develop accurate drug susceptibility testing (DST) for critical medicines, including through sequencing-based tests and strategies for early detection of resistance to the medicines used in regimens.
  • Improve tools for detecting TB infection (i.e. latent TB) and subclinical TB, and testing for risk of progression to active disease.
  • Develop and harness AI and machine learning-based tests.

In conclusion, H.E. Mr Mansukh Mandaviya, Chair of the Stop TB Partnership Board, and Minister of Health and Family Welfare for the Government of India, says: “Beyond everything else, the Global Plan is about people and is dedicated to the millions of people who make daily efforts to help those affected by TB; it promises that ‘we will end TB together’.”

PBD Biotech, in collaboration with its partners, is making a contribution towards the report’s recommendations:

  • Rapid affordable test for diagnosis or triage that does not rely on sputum.
  • Improved tools for detection of latent TB and sub clinical TB.
  • Clinical trials with vulnerable groups in countries with high rates of HIV/AIDS and TB.

The Global Plan to End TB 2023-2030 can be viewed here:
https://www.stoptb.org/global-plan-to-end-tb/global-plan-to-end-tb-2023-2030

Share:

Related posts

Loading...
PCR bead

Novel PCR reaction bead extends global reach of active TB test by removing the cold chain

March 17, 2023
Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR reaction bead for its Actiphage® blood test for active TB. This enables ambient shipping without the need for a cold...
PCR bead

Novel PCR reaction bead extends global reach of active TB test by removing the cold chain

March 17, 2023
Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR...
Actiphage journey 2022

WHO Target Product Profile (TPP) for Tuberculosis

November 14, 2022
For some of the world's most infectious diseases, such as tuberculosis (TB), The WHO has developed target product profiles (TPPs) to assist developers of new diagnostics.
Actiphage journey 2022

WHO Target Product Profile (TPP) for Tuberculosis

November 14, 2022
For some of the world's most infectious diseases, such as tuberculosis (TB), The WHO has developed target product profiles (TPPs)...
Five categories of TB

Who is most at risk of developing TB?

November 14, 2022
Tuberculosis (TB) is a bacterial infection that is spread by inhaling tiny droplets in the air released when an infected person coughs or sneezes. Many people carry the disease without realising, creating a reservoir of disease in a population.
Five categories of TB

Who is most at risk of developing TB?

November 14, 2022
Tuberculosis (TB) is a bacterial infection that is spread by inhaling tiny droplets in the air released when an infected...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
1 2 3 Next »

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!